

Foot/Ankle

Patient Demographics

	Regenexx-SD	Regenexx-C
N	93 patients	49 Patients
Male	59 (63.4%)	24 (49.0%)
Female	34 (35.6%)	25 (51.0%)
Age	50.8 (17-79)	49 (16-71)
BMI	26.2 (18.4-41.3)	34 (20-38)




Same day procedure that isolates a fraction of the bone marrow that's rich in stem cells.



Cultured stem cell procedure where bone marrow mesenchymal stem cells are isolated and then cultured to larger numbers over two weeks.


What's important here?
The patient results detailed on this infographic for -SD are from mostly men who are middle aged and slightly over weight. The patients who received the Regenexx-C procedure were heavier and there were fewer males.

Percentage of Patients Reporting >25% Improvement



Caution! This is registry data, which is not the same as a controlled trial. This means it was collected as patients were treated. The Regenexx-C procedure is not approved by the U.S. FDA and is only performed by independent, licensed third party companies outside of the U.S.

What do these two graphs mean? The graph above represents the percentage of patients who reported >25% relief at various time points after the procedure. For example, at an average of 17.2 months post procedure, 62% of patients who responded reported more than 25% relief for Regenexx-SD. For the graph below, this is the mean reported relief at the last available time point. For example, patients at an average of 17.2 months post Regenexx-SD procedure may have reported anything from no relief, to 50% relief, to 90% relief, the mean of all of those reports was 45% improved while for Regenexx-C it was 55% improved.



This data analysis is part of the 2013 download of patient results tracked in our advanced treatment registry. The data shown here is predominantly for ankle patients that have on average moderate to severe arthritis with some also having instability in the ligaments and/or tendinitis/tendon tears. A few small foot joint patients are also included in this data set. This comparison is for our same day stem cell procedure (Regenexx-SD) offered in the U.S. versus our cultured stem cell procedure only offered outside the U.S.

Same Day vs. Cultured

For demographics, n for age calculation for -SD was 93, for BMI n=77; for -C it was n=49 for age and n=34 for BMI. For the graphs above and below, n was 39 for -SD and n=38 for -C. Likert Improvement from -100% to +100% shown on y-axis. For the graph above, SD patients with either AVN or loose bodies in the joint were excluded, this was not done for -C patients. For both graphs, the averages shown were calculated off the Likert score of the last available time point for that patient.